GSA Capital Partners LLP Has $3.03 Million Stock Position in Kiniksa Pharmaceuticals International, plc $KNSA

GSA Capital Partners LLP raised its position in Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) by 281.9% in the third quarter, according to its most recent disclosure with the SEC. The firm owned 77,984 shares of the company’s stock after acquiring an additional 57,566 shares during the period. Kiniksa Pharmaceuticals International makes up about 0.3% of GSA Capital Partners LLP’s holdings, making the stock its 20th largest position. GSA Capital Partners LLP owned 0.11% of Kiniksa Pharmaceuticals International worth $3,028,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. EverSource Wealth Advisors LLC grew its holdings in shares of Kiniksa Pharmaceuticals International by 140.4% during the second quarter. EverSource Wealth Advisors LLC now owns 911 shares of the company’s stock valued at $25,000 after buying an additional 532 shares during the last quarter. Osaic Holdings Inc. bought a new position in Kiniksa Pharmaceuticals International in the 2nd quarter valued at about $31,000. USA Financial Formulas acquired a new position in Kiniksa Pharmaceuticals International during the 3rd quarter valued at about $32,000. Quantbot Technologies LP purchased a new stake in shares of Kiniksa Pharmaceuticals International in the second quarter worth approximately $43,000. Finally, Farther Finance Advisors LLC lifted its holdings in shares of Kiniksa Pharmaceuticals International by 582.4% in the third quarter. Farther Finance Advisors LLC now owns 1,358 shares of the company’s stock valued at $53,000 after purchasing an additional 1,159 shares in the last quarter. 53.95% of the stock is owned by institutional investors and hedge funds.

Kiniksa Pharmaceuticals International Trading Up 1.5%

NASDAQ:KNSA opened at $45.37 on Tuesday. The firm’s 50 day moving average is $42.29 and its 200 day moving average is $39.07. Kiniksa Pharmaceuticals International, plc has a 12 month low of $18.25 and a 12 month high of $46.65. The stock has a market capitalization of $3.44 billion, a PE ratio of 100.82 and a beta of 0.06.

Insider Buying and Selling at Kiniksa Pharmaceuticals International

In other news, Director Barry D. Quart sold 2,690 shares of the business’s stock in a transaction that occurred on Thursday, February 12th. The shares were sold at an average price of $45.00, for a total value of $121,050.00. Following the sale, the director owned 12,546 shares of the company’s stock, valued at $564,570. The trade was a 17.66% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CFO Mark Ragosa sold 17,845 shares of Kiniksa Pharmaceuticals International stock in a transaction that occurred on Monday, February 9th. The shares were sold at an average price of $43.28, for a total transaction of $772,331.60. Following the completion of the transaction, the chief financial officer owned 12,086 shares of the company’s stock, valued at $523,082.08. This represents a 59.62% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 123,823 shares of company stock valued at $5,244,967 over the last three months. 53.48% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on KNSA. Zacks Research downgraded shares of Kiniksa Pharmaceuticals International from a “hold” rating to a “strong sell” rating in a report on Tuesday, January 13th. Wall Street Zen lowered shares of Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “buy” rating in a research report on Sunday, November 2nd. The Goldman Sachs Group upped their price objective on shares of Kiniksa Pharmaceuticals International from $45.00 to $55.00 and gave the stock a “buy” rating in a research report on Wednesday, October 29th. Weiss Ratings reiterated a “hold (c)” rating on shares of Kiniksa Pharmaceuticals International in a research note on Thursday, January 22nd. Finally, Wedbush boosted their target price on Kiniksa Pharmaceuticals International from $48.00 to $50.00 and gave the stock an “outperform” rating in a research note on Tuesday, January 13th. Six investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $52.33.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.